IntroductionThe first goal of treating continual section continual myeloid leukemia (CML-CP) is to stop development to extra aggressive accelerated or blast section CML,...
Jennifer R. Brown, MD, PhDFastened-duration acalabrutinib (Calquence) plus venetoclax (Venclexta) with or with out obinutuzumab (Gazyva) within the frontline setting elicited a statistically...